Patrys Limited (DE:A1N)
BERLIN:A1N
Holding DE:A1N?
Track your performance easily

Patrys Limited (A1N) Stock Price & Analysis

0 Followers

A1N Stock Chart & Stats


Financials

Annual

A1N FAQ

What was Patrys Limited’s price range in the past 12 months?
Currently, no data Available
What is Patrys Limited’s market cap?
Currently, no data Available
When is Patrys Limited’s upcoming earnings report date?
Patrys Limited’s upcoming earnings report date is Feb 21, 2025 which is in 136 days.
    How were Patrys Limited’s earnings last quarter?
    Patrys Limited released its earnings results on Aug 23, 2024. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
      Is Patrys Limited overvalued?
      According to Wall Street analysts Patrys Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Patrys Limited pay dividends?
        Patrys Limited does not currently pay dividends.
        What is Patrys Limited’s EPS estimate?
        Patrys Limited’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Patrys Limited have?
        Patrys Limited has 2,057,447,300 shares outstanding.
          What happened to Patrys Limited’s price movement after its last earnings report?
          Patrys Limited reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
            Which hedge fund is a major shareholder of Patrys Limited?
            Currently, no hedge funds are holding shares in DE:A1N
            ---

            Patrys Limited Stock Smart Score

            Company Description

            Patrys Limited

            Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 and PAT-DX1-NP, and PAT-LM1. Its lead technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody which penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Qube Holdings Ltd.
            Noxopharm Ltd.
            Vectus Biosystems Limited
            Chimeric Therapeutics Ltd.
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis